The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.
 
Rachel Woodford
No Relationships to Disclose
 
Deborah Zhou
No Relationships to Disclose
 
Peey-Sei Kok
Honoraria - AstraZeneca/MedImmune; Pfizer
Consulting or Advisory Role - MSD
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Pfizer
Other Relationship - AstraZeneca (Inst); Roche (Inst)
 
Sally Lord
No Relationships to Disclose
 
Michael Friedlander
Honoraria - AstraZeneca; GlaxoSmithKline; Lilly; MSD; Novartis; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; Lilly; MSD; Novartis; Takeda
Speakers' Bureau - ACT Genomics; AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Ian Marschner
Consulting or Advisory Role - Abbvie (Inst)
Research Funding - Janssen (Inst)
 
John Simes
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Chee Khoon Lee
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck KGaA; MSD Oncology; Novartis; Pfizer; Roche; Takeda; Yuhan
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Novartis; Takeda; Yuhan
Research Funding - AstraZeneca (Inst); Merck KGaA (Inst); Roche (Inst)